Harmonization of tumor mutation burden testing with comprehensive genomic profiling assays: an IQN Path initiative

Background Although conflicting results emerged from different studies, the tumor mutational burden (TMB) appears as one of most reliable biomarkers of sensitivity to immune checkpoint inhibitors. Several laboratories are reporting TMB values when performing comprehensive genomic profiling (CGP) wit...

Full description

Bibliographic Details
Main Authors: Nicola Normanno, Paolo Chiodini, Riziero Esposito Abate, Raffaella Pasquale, Alessandra Sacco, Vittorio Simeon, Monica Rosaria Maiello, Daniela Frezzetti
Format: Article
Language:English
Published: BMJ Publishing Group 2024-02-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/12/2/e007800.full

Similar Items